Skip to main navigation Skip to search Skip to main content

In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2

Research output: Contribution to journalArticlepeer-review

Abstract

Durlobactam, a diazabicyclooctane β-lactamase inhibitor, exhibits direct antibacterial activity by binding to penicillin-binding protein 2 (PBP2). We generated a mutant strain of New Delhi metallo-β-lactamase-producing Escherichia coli with a durlobactam minimum inhibitory concentration of 2 µg/mL, representing a 16-fold increase from baseline, by exposing it to increasing concentrations of durlobactam. Resistance was attributed to a point mutation in the mrdA gene, resulting in a V522I substitution in PBP2.

Original languageEnglish
JournalAntimicrobial agents and chemotherapy
Volume69
Issue number11
DOIs
Publication statusPublished - 11-2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2'. Together they form a unique fingerprint.

Cite this